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Abstract: Clonal expansion of human T-lymphotropic virus type-1 (HTLV-1) infected cells in vivo
is well documented. Unlike human immunodeficiency virus type 1 (HIV-1), HTLV-1 plasma RNA
is sparse. The contribution of the “mitotic” spread of HTLV-1 compared with infectious spread
of the virus to HTLV-1 viral burden in established infection is uncertain. Since extrachromosomal
long terminal repeat (LTR) DNA circles are indicators of viral replication in HIV-1 carriers with
undetectable plasma HIV RNA, we hypothesised that HTLV-1 LTR circles could indicate reverse
transcriptase (RT) usage and infectious activity. 1LTR and 2LTR DNA circles were measured in
HTLV-1 cell lines and peripheral blood mononuclear cells (PBMC) of asymptomatic carriers (ACs)
and patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or adult
T cell leukaemia/lymphoma (ATLL). 1LTR DNA circles were detected in 14/20 patients at a mean
of 1.38/100 PBMC but did not differentiate disease status nor correlate with HTLV-1 DNA copies.
2LTR DNA circles were detected in 30/31 patients and at higher concentrations in patients with
HTLV-1-associated diseases, independent of HTLV-1 DNA load. In an incident case the 2LTR DNA
circle concentration increased 2.1 fold at the onset of HAM/TSP compared to baseline. Detectable
and fluctuating levels of HTLV-1 DNA circles in patients indicate viral RT usage and virus replication.
Our results indicate HTLV-1 viral replication capacity is maintained in chronic infection and may be
associated with disease onset.
Keywords: long terminal repeat; LTR DNA circles; human T-lymphotropic virus; HTLV;
viral replication
1. Introduction
Human T-lymphotropic virus type-1 (HTLV-1) is a complex retrovirus, in the genus Deltaretrovirus
of the subfamily Orthoretrovirinae of the Retroviridae family of viruses. It is an oncovirus
causing adult T cell leukaemia/lymphoma (ATLL) [1,2] and is associated with a variety of
Viruses 2016, 8, 80; doi:10.3390/v8030080 www.mdpi.com/journal/viruses
Viruses 2016, 8, 80 2 of 15
inflammatory conditions, most notably HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [3,4]. Retroviruses carry a diploid plus-strand RNA genome [5] as well as viral enzymes
reverse transcriptase (RT), integrase, protease and RNase H. Once released into the cytoplasm, viral
RNA is transcribed into double stranded linear DNA flanked directly by long terminal repeats (LTRs).
The DNA is transported into the nucleus within the pre-integration complex. In the nucleus the
linear un-integrated DNA is either inserted into the host genome or circularised (Figure S1) [6–8]. The
circular DNA has been found in different configurations such as 1LTR [7,9,10], tandem 2LTR [11,12]
and heterogeneous 2LTR DNA circles [13] depending on the number and position of the LTRs. They
are generally assumed to be dead-end by-products but it has been suggested that they are functional
or even cytotoxic [14,15]; at times, un-integrated DNA can represent 99% of total viral DNA [16].
Human immunodeficiency virus type 1 (HIV-1) 2LTR circles have been used as an experimental
marker of RT activity [17], the nuclear transport of linear DNA [18] and the ongoing replication of
the HIV-1 latent reservoir in patients on antiretroviral therapy [19]. HIV-1 2LTR circle concentration
decreases with RT inhibition and increases with integrase inhibition; its consistent detection and change
in concentration shows that even with long-term quadruple antiretroviral therapy HIV-1 continues to
produce new DNA and is therefore not latent [19].
Recent reviews model HTLV-1 replication [20,21] but, at least in vivo, HTLV-1 viral replication
capacity is still not fully understood. HTLV-1 transmission is known to be preferentially cell associated
as cell free products of HTLV-1 patients have often, though not always [22], been found to be
non-infectious [23]. More recently, however, cell-free virus biofilm assemblies have been shown
to be capable of infecting lymphocytes and, by preference, dendritic cells [24]. HTLV-1 RNA is
virtually undetectable in patients’ plasma [25] leading to the assumption of no or little RT usage in vivo.
However, we believe that a number of viral replicative cycles must occur in a new host to establish
infection [26] and sequence variations have been observed within families following mother-to-child
transmission (MTCT) [27]. Indeed, the kinetics of acute HTLV-1 infection in patients that had received
organ transplantation from an HTLV-1 infected individual have recently been demonstrated, revealing
that proviral load set point and seroconversion was reached within six weeks through clonal expansion
but also via a high rate of infectious spread [28].
The HTLV-1 viral load is reported as the total viral DNA detected in 100 peripheral blood
mononuclear cells (% PBMCs) often referred to as proviral load (PVL). This can vary from <0.001%
to >100%; is known to be low (<1%) in 50% of asymptomatic carriers (ACs) and high (>1%) in all
patients with ATLL and HAM/TSP, but remains remarkably stable over several years in patients
without ATLL [29]. Several HIV-1 antiretrovirals have been shown to be effective HTLV-1 enzyme
inhibitors in vitro [30,31]. However no drug intervention to date has consistently decreased the HTLV-1
total DNA in humans [32–35], although a significant reduction was detected in STLV-1 infected
macaques treated with sodium valproate (used as a histone deacetylase inhibitor) and the nucleoside
analogue RT inhibitor, zidovudine [36]. HTLV-1 infection is maintained through Tax driven clonal
expansion of HTLV-1 infected CD4+/CD25+ T cells, but the virus is able to spread in vitro from
cell-to-cell through the virological synapse [37–40] and through the exchange of transient biofilm-like
extracellular virus particles held on the surface of an infected cell [41]. How much this spread is
contributing to the DNA concentration in vivo remains unknown [42]. An interference with viral
replication may reduce transmission and the risk of developing HTLV-1 associated disease through
resetting the total DNA burden at a lower set point.
The detection and quantification of 1 and 2LTR HTLV-1 DNA circles in vivo could be a biomarker
of continuous HTLV-1 viral replication in parallel to its mitotic expansion; this study was designed to
address this hypothesis.
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2. Materials and Methods
2.1. Cell Culture
MT-2 cells were cultured at 37 ˝C with 5% CO2 in Roswell Park Memorial Institute (RPMI)
1640 medium, supplemented with 100 IU/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine,
10 mM HEPES and 10% heat inactivated FCS; HuT 102 cells were cultured in the same media with
the inclusion of 1 mM sodium pyruvate and 4500 mg/mL glucose (all cells were purchased from the
ATCC, Teddington , UK; reagents were from Invitrogen, Paisley, UK or PAA Laboratories, Yeovil, UK).
2.2. In-Vivo Studies
Stored DNA samples from PBMCs of 48 HTLV-1 positive, HIV negative, patients were tested
retrospectively. Forty-seven samples donated by patients attending the National Centre for Human
Retrovirology (NCHR) at Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK and
DNA from one patient at the HTLV Centre at Bahiana Medical School, Salvador, Brazil were studied.
All samples were donated after written informed consent to participate in research approved by the UK
National Research Ethics Service, Oxford “A” Local Research Ethics Committee (Ref: 09/H0606/106)
or the institutional review board of the Oswaldo Cruz Foundation, and the National Commission
on Ethics in Research (CONEP record: 15271), Brazilian Ministry of Health. Insufficient DNA was
available to test all samples for 1 and 2LTR. For the 1LTR studies 20 samples were available: six
patients were ACs, ten had HAM/TSP and four ATLL; for the 2LTR studies 31 patient samples
were available: 13 ACs, ten HAM/TSP and eight ATLL (five with lymphoma, an aggressive type of
ATLL and three with more indolent disease: one with chronic ATLL in complete remission and two
with cutaneous lymphoma). Four samples were duplicated in 1LTR and 2LTR testing, giving a total
of 47 patient samples.
2.3. DNA Extraction and Amplification
All DNA were extracted from the cell lines and PBMCs as previously published [43]. Circular, low
molecular weight DNA was extracted from total genomic DNA through QIAprep spin miniprep
kit (Qiagen, Manchester, UK) according to the manufacturer’s protocol and quantified using a
nanodrop spectrophotometer (ThermoScientific, Loughborough, UK). Primers (Table 1 and Figure S1)
for detection of 1 and 2LTR HTLV-1 DNA circles using classical and nested PCR were designed using
Primer3 [44,45] by alignment of the AKT strain of the complete HTLV-1 genome, accession number
J02029.1 [5]. For the detection of 1LTR circle DNA using the classical PCR protocol the primers were
designed in the pX and gag region. For the 2LTR DNA circles, primers were seated either side of the
LTR-LTR junction. Primers used for the detection of low copy number 1 and 2LTR DNA circle in the
nested PCR protocol were designed in the same fashion (Table 1). National Center for Biotechnology
Information (NCBI) Blast database program was used to confirm that the designed sequences did not
match other published DNA sequences. Primers were manufactured by Invitrogen or Sigma (Dorset,
UK). Concentrations of LTR circles were measured at two time points, immediately and four hours
post venepuncture, to observe whether there were time dependent variations.
Table 1. Sequences of the primers and probes used.
Primer/Probe Sequence Product Size
1LTR probe
CTCTCACACGGCCTCATACAGTACTCTTCCTTTCAT
AGTTTACATCTCCTGTTTGAATTATTCCCTAGGCAA
TGGGCCAAATCTTTTCCCGTAGCGCTAG
100 bp
1LTR FWD CTCTCACACGGCCTCATACA 940 bp
1LTR REV CTAGCGCTACGGGAAAAGAT
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Table 1. Cont.
Primer/Probe Sequence Product Size
1LTR nested probe
CACCAACATCCCCATTTCTCGTACTCTTCCTTTCATA
GTTTACATCTCCTGTTTGAATTATTCCCTAGGCAATG
GGCCAAACTGGCAATGGGCCAAATCT
100 bp
1LTR nested FWD CACCAACATCCCCATTTCTC 840 bp
1LTR nested REV AGATTTGGCCCATTGC
2LTR probe
ATGAGCCCCAAATATCCCCCGGGGGTACTCTTCCTTT
CATAGTTTACATCTCCTGTTAGTTGAATTATTCCCTAG
GCAGTTCTGCGCCGTTACAGATCGA
100 bp
2LTR FWD ATGAGCCCCAAATATCCCCCGGGG 611 bp
2LTR REV TCGATCTGTAACGGCGCAGAAC
2LTR nested probe
AGCCACCGGGAACCACCCATGTACTCTTCCTTTCAT
AGTTTACATTTGTTTGAATTATTCCCTAGGCAATGGG
CCAGGTCGAGACCGGGCCTTTGTC
100 bp
2LTR nested FWD AGCCACCGGGAACCACCCAT 307 bp
2LTR nested REV GACAAAGGCCCGGTCTCGACCT
2.4. PCR Reaction Protocol
Classical PCR: DNA extracted from 6 ˆ 105 cells was used for amplification in 50 µL reaction
volumes containing 100 pM of each primer, 200 µM dNTPs, 2 mM MgCl, 1 x green GoTaq reaction
buffer (Promega, Southampton, UK) and 1U GoTaq polymerase (Promega). The cycling conditions on
an MJ research PTC 200 Thermal Cycler were: denaturation step 5 min at 94 ˝C, followed by 35 cycles
of amplification consisting of 1 min at 95 ˝C, 30 s at 62 ˝C (1LTR) or 66 ˝C (2LTR), 5 min at 72 ˝C,
and a final elongation step at 72 ˝C for 5 min. Where necessary, one microliter of the first round
(classical) product was transferred to 49 µL of reaction mix containing the reagents at the same final
concentrations as described for the classical PCR for the nested PCR. Cycling conditions for the
nested PCR were as follows: denaturation step 5 min at 94 ˝C, followed by 35 cycles of amplification
consisting of 1 min at 95 ˝C, 30 s at 66 ˝C, 5 min at 72 ˝C, and a final elongation step at 72 ˝C for 5 min.
12 µL from each reaction was separated on a 2% agarose gel (NuSieve 3:1, Lonza, Cambridge, UK) and
visualised by ethidium bromide (Sigma) staining under UV light using the Syngene gel documentation
system and GeneSys software. The identity of the amplicons were confirmed through purification of
the PCR product from the gel through PCR Purification Kit (Qiagen) according to the manufacturer’s
protocol and sequencing 400 bp on each side with the forward and reverse primers. The sequencing
was carried out by the MRC CSC Genomic Core Laboratory at Hammersmith Hospital, London, UK.
Standard sequencing generates 700–800 bases of readable sequence from a single sequence. The NCBI
Blast program was used to identify the DNA sequence.
2.5. Quantification of LTR DNA Circles and HTLV-1 PVL
LTR DNA circles were determined by serial dilution of purified sample DNA in distilled
water followed by amplification of quadruplicates at each dilution. The quantity of LTR circles
were determined from Poisson’s distribution at the lowest concentration of DNA that resulted in
amplification in at least one of the replicates, where load = ´logn¨Fox dilution, and Fo is the number
of negative tests/the number of tests. HTLV-1 PVL was measured using real-time PCR (LightCycler,
Roche, Mannheim, Germany) as previously described [46].
2.6. Controls
One hundred base-pair DNA was designed to spike HTLV-1 negative DNA as positive controls
for primer amplification. MT-2 cells were found to contain LTR DNA circles and were used as positive
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controls thereafter. Negative controls were DNA isolated from HTLV-1 negative cord and donor
PBMCs or water.
2.7. LTR DNA Localisation
MT-2 cells were treated with triton-sucrose buffer (0.32 M sucrose, 1% Triton X-100, 5 mM MgCl2,
10 mM Trio-HCL, pH 7.5) and centrifuged for 1 min at 14,000 g in order to separate cytoplasm from
nucleus. DNA was extracted using Qiagen DNA mini kit according to the manufacturer’s protocol
and 1LTR DNA circles were quantified as above.
2.8. Reverse Transcriptase Inhibitory Study
Tenofovir disoproxil fumarate (TDF) was obtained through the AIDS Research and Reference
Reagent Program, NIAID, NIH. MT-2 cells were cultured in the presence or absence of TDF at its
known inhibitory concentration 50 (IC50), 0.01 µmol/L with media changes and TDF refreshment at
three-day intervals. Growth rates were compared by taking regular cell counts. 1LTR DNA circles
were quantified in MT-2 DNA extracted and purified by QIAprep spin miniprep on days 0, 17 and 28.
2.9. Cell Entry Inhibitor Study
MT-2 cells were cultured as previously described for 10 days with and without 10 µM Pcr-400
with media changes and drug refreshment at three-day intervals [47]. Aliquots of 6 ˆ 106 cells were
obtained on days 3, 7 and 10; DNA was extracted and purified from both treated and control cells by
QIAprep spin miniprep and 1LTR DNA circles were quantified as described above.
2.10. Statistical Analysis
Data were analysed in SPSS (v14) or GraphPad Prism (v6.02) using parametric (t-test) and
linear regression model for comparing two or more continuous variable. Non-parametric tests
(Mann-Whitney Test) were used for correlating categorical with continuous variables and chi-square
(Pearson Chi-Square Test for large >5, and Fisher’s Exact test <5 sample size) for categorical variables.
One way non-parametric ANOVA tests with Dunn’s multiple comparison correction or non-parametric
t-test were used where appropriate. Results were considered statistically significant if a p-value < 0.05
was achieved.
3. Results
3.1. Detection, Localisation, Quantification of LTR DNA Circles
We previously presented preliminary data on circularised LTR DNA concentration in MT2
cells [48] but now with revised methodology and using matched cell extracts we have found both 1
and 2LTR DNA circles in two cell lines: MT-2 and HuT 102 (Table 2) originally derived from HTLV-1
infected individuals [2,49,50]. 1LTR DNA circles were approximately half as frequent as 2LTR DNA
circles in MT-2 and HuT 102 cell lines. In localisation studies, LTR DNA circles were detected
at 1 copy/6000 MT-2 cells in cytoplasm and at 1 copy/87 MT-2 cells in the nuclei.
Table 2. Quantification and ratio calculation of 1 long terminal repeat (LTR) and 2LTR DNA circles in
two cell lines carrying human T-lymphotropic virus type-1 (HTLV-1).
Cell Line Limit of Detection in 1 µg DNA Ratio of 1:2 LTR
1LTR 2LTR
MT-2 8.79 copies 14.67 copies 1:1.7
HuT 102 5.51 copies 11.03 copies 1:2
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3.2. Biomarker for Persistent RT Usage
MT-2 cells were cultured with and without TDF, a potent RT inhibitor, or Pcr-400, a HTLV-1
entry inhibitor at their respective inhibitory concentration 50 (IC50); the drugs did not impair cell
proliferation or viability (data not shown). Whilst LTR circle concentration decreased in the presence
of TDF: 1 copy/0.6 MT-2 cells (day 0) compared with 1 copy /2.1 MT-2 cells (day 17 and day 28), it did
not change over time with entry inhibitor Pcr-400 indicating, albeit futile, persistent viral RT enzyme
usage and potential recycling of virus intracellularly.
3.3. LTR DNA Circles in HTLV-1 Infected Patients
In total, PBMCs of 47 chronically infected HTLV-1 carriers were tested. 1LTR DNA circles were
measured in 20- and 2LTR DNA circles in 31-PBMC samples with dual testing in four samples.
Patient demographics are outlined in Table S1. In order to detect a potential decrease of LTR DNA
circle concentration in blood samples over time due to sample aging, LTR DNA circle levels were
compared in four blood samples where DNA was extracted immediately or after a four hour delay
post venepuncture of patients. LTR DNA circle levels were found to be independent of the timing of
DNA extraction (data not shown).
As expected [29], PVL was significantly lower, p = 0.0019, among ACs (median of 4.5%) compared
with patients with HAM/TSP (median of 16.40) or ATLL (median of 20.20), p = 0.0010, with no
significant difference between HAM/TSP and ATLL patients (Figure 1). 1LTR DNA circles were
detected in 14/20 (67%) patients: 4/6 (67%) ACs, 7/10 (70%), HAM/TSP and 3/4 (75%) ATLL.
The presence of 1LTR DNA circles did not differ between ACs and patients with HAM/TSP (Fisher’s
Exact test, p = 0.15) or ATLL (p = 0.6). 1LTR DNA circle concentration did not differ significantly
between the ACs, HAM/TSP or ATLL groups and was not a predictor of clinical status (Table 3).
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Horizontal  line  represents median PVL within each group. Statistical differences between groups 
were  calculated  using  non‐parametric  one‐way  ANOVA  with  Dunn’s  multiple  comparison 
correction. **: p < 0.01, ***: p < 0.001. 
Figure 1. u an T-ly photropic virus type-1 ( TLV-1) proviral load (PVL) is higher in TLV-1
infected patients ith TLV-1 associated disease than in asy pto atics. PVL fro patients in three
diagnostic groups: asymptomatic (n = 19), HTLV-1-associated myelopathy/tropical spastic paraparesis
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***: p < 0.001.
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Table 3. 1LTR DNA circle detection in samples from patients with HTLV-1. Patients are denoted a code.
VL% = HTLV-1 DNA copies/100 PBMCs, 1LTR% = number of 1LTR DNA circles/100 PBMCs. Code
prefix H = ACs, prefix T = HAM/TSP, prefix L = ATLL. * denotes acute ATLL.
Patient VL% (Range) 1LTR 1LTR%
HBK 129 + 0
HBU 3.94 + 0
HCT 0.08 + 0.0023
HEF 2.39 + 0
HT 23.4 - 0
HX 0.02 - 0
ACs mean 26.5 (0.02–129)
TAF 76.8 + 0.0048
TAN 16 + 0.0048
TAQ 12.3 + 0.0023
TAS 17.4 + 0.00048
TBW 12.8 + 0.0023
TBX 13.28 + 0.000048
TBR 22.9 + 0
TBJ 51 - 0
TBU 10.2 - 0
TCD 43.7 - 0
HAM mean 27.6 (10–77)
LER 76.75 + 0.00023
LEV* 124.7 + 0.11547
LEY 77.1 + 0.0048
LP4 96.3 - 0
ATLL mean 94 (77–125)
2LTR DNA circles were detected in 28/31 (90%) PBMCs from patients using classical PCR and
in 30/31 (97%) by nested PCR. 2LTR DNA circles were not detected even with nested PCR in one
patient, who had a PVL of 0.01%. 2LTR DNA circles were detected at significantly higher concentrations
in patients with diagnosed disease (HAM/TSP and ATLL) compared to ACs (p = 0.003) (Figure 2A),
whilst there was no significant difference between patients with HAM/TSP and ATLL (Figure 2B).
This association with disease was also detected when ACs with high PVL, similar to patients with
HAM/TSP, were compared to HAM/TSP and ATLL patients (Table 4). It is important to point out
that none of the patients with ATLL suffered from the acute leukemic form and that the patient with
chronic ATLL was in complete remission. Therefore the DNA was extracted from non-cancerous
HTLV-1 infected PBMCs reflecting the background HTLV infection rather than the transformed cells.
This makes the results comparable to asymptomatic patients and those with HAM/TSP.Viruses 2016, 8, 80  9 of 16 
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Figure  2.  2LTR DNA  circle  level  is  higher  in HTLV‐1  infected  patients with HTLV‐1  associated 
diseases compared to asymptomatics. In panel (A), 2LTR DNA circle levels in individual patients are 
plotted for asymptomatics (■ n = 10) or symptomatics (▲ n = 18). In (B), the same data is plotted for 
patients diagnosed as asymptomatic (■), HAM/TSP (● n = 10) or ATLL (▲ n = 8). Mean 2LTR DNA 
circle  levels  within  each  group  are  depicted  by  the  horizontal  bar;  statistical  comparisons  are 
performed  using  non‐parametric  t‐test  (A)  or  a  non‐parametric  one‐way  ANOVA  with  Dunn’s 
multiple comparisons correction. *: p < 0.05, **: p < 0.01. 
A  correlation  between  PVL  and  2LTR  DNA  circle  concentration  was  not  detected   
(Figure 3A–C). This  indicates  the on‐going usage of viral RT and viral DNA production, despite 
established, chronic cellular infection, which is independent of the number of PBMCs infected. 
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established, chronic cellular infection, which is independent of the number of PBMCs infected. 
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Figure 2. 2LTR DNA circle level is higher in HTLV-1 infected patients with HTLV-1 associated diseases
compared to asymptomatics. In panel (A), 2LTR DNA circle levels in individual patients are plotted
for asymptomatics ( n = 10) or symptomatics (N n = 18). In (B), the same data is plotted for patients
diagnosed as asy ptomatic (), HAM/TSP ( n = 10) or ATLL (N n = 8). Mean 2LTR DNA circle levels
within each group are depicted by the horizontal bar; statistical comparisons are performed using
non-parametric t-test (A) or a non-parametric one-way ANOVA with Dunn’s multiple comparisons
correction. *: p < 0.05, **: p < 0.01.
Table 4. 2LTR DNA circle detection in samples from patients with HTLV-1. Patients are denoted a
code. VL% = HTLV-1 DNA copies/100 PBMCs, 2LTR% = number of 2LTR DNA circles/100 PBMCs.
Code prefix H = ACs, prefix T = HAM/TSP, prefix L = ATLL. * denotes acute ATLL.
Patient VL% (Range) 2LTR 2LTR%
HBU 4.5 + 0.0005184
HBZ 5.5 + 0.0015246
HBF 7.9 + 0.00079
HBE 14.1 + 0.00141
HAO 0.21 + 0.0000021
HBK 10.3 Nested +
HBX 11.23 + 0.003112956
HCH 15 + 0.04158
HDH 0.04 + 0.0000004
HDO 0.01 - Undetectable
HDY 0.06 Nested +
HFE 15.33 + 0.04249476
HT-UV1 0.82 + 0.00454608
ACs mean 6.54 (0.01–15)
TBP 6.1 + 0.0023424
TBW 13.1 + 0.00150912
TBG 16.8 + 0.0465696
TBA 17.7 + 0.0101952
TAL 15.4 + 0.088704
TAT 10.4 + 0.0029952
TBZ 18.83 + 0.2169216
TCJ 16.95 + 0.469854
TCP 13.07 + 0.01505664
TCQ 12.57 + 0.1448064
HAM mean 14.09 (6–19)
LEU 7.6 + 0.00347776
LGH 13.88 + 0.003847536
LGA 21.68 + 0.0624384
LFE 15.2 + 0.210672
TBX 14.57 + 0.00839232
LFK * 8.2 + 0.0031488
LFA * 21.9 + 0.063072
LFP * 5.48 + 0.00631296
ATLL mean 13.56 (5–22)
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From our patient samples, we calculated that based upon patient PVL, on average, DNA from
529 ˘ 296 infected cells (2800 ˘ 1350 total PBMCs) were required to detect one 2LTR DNA circle in
ACs. DNA from 163 ˘ 73 (1811 ˘ 852 PBMCs) infected cells were required for the detection of one
2LTR DNA circle in patients with HAM/TSP and DNA from 148 ˘ 49 (1484 ˘ 477 PBMCs) infected
cells were required for detection of one 2LTR DNA circle in patients with ATLL.
A correlation between PVL and 2LTR DNA circle concentration was not detected (Figure 3A–C).
This indicates the on-going usage of viral RT and viral DNA production, despite established, chronic
cellular infection, which is independent of the number of PBMCs infected.Viruses 2016, 8, 80  10 of 16 
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from patients with HTLV‐1 required to detect 2LTR DNA circles in those diagnosed as asymptomatic 
(n = 10)  (A); HAM/TSP  (n = 10)  (B) or ATLL  (n = 8);  (C)  is plotted against  the patients’ PVL  (%). 
Correlation regression was calculated using line of best fit and r2 in PRISM software. 
3.4. Biomarker for HTLV Disease Progression 
Stored DNA  of  PBMCs  of  one HTLV‐1  positive  patient with  documented  onset  of  definite 
HAM/TSP  was  tested.  DNA  samples  were  available  from  two  time  points:  in  2004  when  the 
individual was asymptomatic and in 2012 following the onset of HAM/TSP. The 2LTR DNA circle 
Figure 3. There is no correlation between PVL and 2LTR DNA circle levels. The number of PBMCs from
patients with HTLV-1 required to detect 2LTR DNA circles in those diagnosed as asymptomatic (n = 10)
(A); HAM/TSP (n = 10) (B) or ATLL (n = 8); (C) is plotted agai st the patients’ PVL (%). Correlation
regression was calculated using line of best fit and r2 in PRISM software.
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3.4. Biomarker for HTLV Disease Progression
Stored DNA of PBMCs of one HTLV-1 positive patient with documented onset of definite
HAM/TSP was tested. DNA samples were available from two time points: in 2004 when the individual
was asymptomatic and in 2012 following the onset of HAM/TSP. The 2LTR DNA circle concentration
was 2.06 fold higher at onset of disease, after adjusting for the rise in HTLV-1 PVL, which had increased
1.86 fold (1.62% to 3.01%) when symptomatic compared to the asymptomatic status (Figure S2). 1LTR
DNA circles were undetectable in the DNA from this patient using classical or nested PCR.
4. Discussion
LTR DNA circles are used to detect on-going viral replication in HIV infected individuals receiving
antiretroviral therapy. Two randomised clinical trials and two cohort studies of antiretroviral therapy
in patients with HTLV-1 did not show a significant change in in vivo PVL [32–35], which is thought to
be mainly maintained through clonal expansion. Typically, in vivo HTLV-1 DNA levels are established
early in infection and do not vary over time [51]. However, very little is known about HTLV-1 RT
usage, the production of de novo virus and LTR DNA circle by-products, its effects on the total HTLV-1
viral load, disease development and progression during chronic HTLV-1 infection.
HTLV-1 extrachromosomal DNA was reported to be present up to 24 months after virus
integration in HTLV-1 positive HL-60 cell lines; the amount of extrachromosomal DNA fluctuated over
time possibly due to the replication and re-infection capacity of the virus [52]. Clones with multiple
integrated HTLV-1 DNA were those with persistent extrachromosomal DNA. This was presumed
to be the result of intracellular virus production and cell re-infection [14,15,17,18]. Another group
detected 2LTR DNA circles in HTLV-1 and -2 positive cell lines but only in the PBMCs of one of seven
patients with HTLV-1 ATLL, and not in any asymptomatics or HAM/TSP patients [53]. We recently
contributed to findings assessing 2LTR levels in organ transplant recipients from an HTLV-1 infected
donor: 2LTR DNA circles were detectable in all three recipients and the levels largely mirrored PVL
fluctuations [28] suggestive of acute infectious spread.
Twenty years on, the relative contribution of cell proliferation and infectious spread to HTLV-1
viral load in chronic infection remains relatively unknown. We therefore decided to explore a marker
of the HTLV-1 viral replication activity, and detected 1 and 2LTR DNA circles in both cell lines and
patients’ samples. Typically, 2LTR DNA circles are investigated in HIV-1 research and we confirm that
2LTR DNA circles were more consistently found in HTLV-1.
In order to increase specificity we aimed to capture mainly small molecule DNA through a
selective purification methodology and by using a low concentration of DNA molecules (~ 400 ng).
This reduced the risk of hybridization of any linear compounds and linear amplification, as suggested
previously [54]. Traditionally the whole LTR DNA circle is not amplified due to its large product size
(~ 10 kb), but the orientation of the specifically designed primers allows the amplification across one
LTR (1LTR) or the junction of two LTRs (2LTR), which are flanked by viral genome only. This excludes
the amplification of integrated DNA.
With the assumption that RT usage precedes LTR circle production, we attempted to inhibit
entry and reverse transcription. In cell lines, LTR circle concentrations decreased in the presence of
the most potent ex vivo RT inhibitor [30], TDF, but not with an HTLV-1 entry inhibitor Pcr-400. This
indicates recycling of viral RNA through persistent RT usage and LTR circle production in chronic
infection, which is independent from new viral entry. Other publications also support the perception
that HTLV-1 has a replicative potential in vivo via dendritic cell infection and potential continuous
spread to lymphocytes [24,55,56].
Unlike previous reports, in our study LTR circles were detected not only in chronically infected
cells lines, but also in the PBMCs of almost all HTLV-1 positive patients (46/47). The formation of LTR
circles seems to be less common in HTLV-1 than in HIV-1 infected cells, which supports the perception
that HTLV-1 is less replication active. This might provide the virus with survival benefits. It has
been suggested that an accumulation of DNA circles is highly cytopathic, increasing cell death in HIV
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infected cells [14,57]. Also T cells containing less replicative viruses may more readily escape a HTLV-1
specific cytotoxic T cell response [58].
Although 1 and 2LTR DNA circles could be found in HTLV-1 infected patients, 2LTR circles were
more commonly detected. The finding that 2LTR DNA circle concentration consistently differentiated
symptomatic patients from ACs, independent of total, linear, DNA concentration, was surprising. This
difference persisted, even when 2LTR DNA circle levels of ACs with high PVL were compared to
patients with HAM/TSP or with chronic/cutaneous ATLL. 2LTR DNA circles did not differentiate
between HAM/TSP and ATLL patients. In addition, we observed a significantly higher 2LTR DNA
circle level in the patient with recent onset of HAM/TSP compared to their asymptomatic state.
Together, these observations suggest an association between 2LTR DNA levels and clinical disease
activity. To confirm this LTR DNA circles should be monitored longitudinally in a considerable cohort
of ACs to measure variations of LTRs over time with and without disease onset.
These results not only indicate that HTLV-1 actively replicates in chronic infection, but also raise
the following four questions. (1) How much does on-going RT usage contribute to PVL and promote
cell-to-cell perhaps even human-to-human transmission? The reduction of LTR DNA circles with the
RT inhibitor TDF in vitro poses the question (2) as to whether HTLV-1’s infectivity may be modifiable?
(3) Could active viral replication contribute to pathogenesis and is viral replication increased in patients
with active disease? Increased viral activity may lead to increased viral antigen expression and local
recruitment of HTLV-1 specific cytotoxic T lymphocytes, cytokine release and tissue damage. 2LTR
DNA circle levels may be a potential biomarker of disease onset/risk or treatment response; (4) Are
HTLV-1 LTR DNA circles functional in themselves? It has been suggested that HIV-1 circles are
transcriptionally active, producing functionally active proteins such as tat, env, nef [59–64].
5. Conclusions
Despite presumed latency or inactivity of HTLV-1, 1 and 2LTR DNA circles are present in
chronically infected cell lines and in patient PBMCs, indicating ongoing viral RT usage. Monitoring
2LTR DNA circle concentration might be useful to identify early patients in the process of disease
development and in this manuscript we provide novel methodology for this assessment. The
clinical application of HTLV-1 2LTR DNA circles needs to be tested further in larger patient cohorts
longitudinally and is likely to be achieved in multicentre collaborations.
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